The Lancet study unveils exciting findings on retatrutide as a novel treatment for type 2 diabetes
Researchers performed a phase II randomized clinical trial (RCT).
Source: news-medical.net
Page 7 - Agonist News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Agonist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Agonist Today - Breaking & Trending Today
TOS members unveil new research about anti-obesity medications at ADA annual meeting
Multiple members of The Obesity Society (TOS) unveiled new research about several anti-obesity medications in development at this year's annual meeting of the American Diabetes Association (ADA) held June 23–26.
Source: news-medical.net
Oral semaglutide outperforms other medications in type 2 diabetes treatment, significantly reducing HbA1c and body weight
Orally administered semaglutide shows significant efficacy in reducing HbA1c and body weight in patients with type 2 diabetes compared to other treatments. The study includes a large number of participants from multiple trials.
Source: news-medical.net
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide, a PTHR1 Agonist Entering Phase 3 for the Treatment of Hypoparathyroidism, in Chicago on June 16, 2023
LYON, France and CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced
Source: finanznachrichten.de
_1b78fec41a5143afb6e7b9ad317023d2-620x480.jpg)
How does tirzepatide stimulate insulin secretion?
Tirzepatide, a drug approved for diabetes and on the fast track for approval as a weight loss therapy, works through a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy balance, Duke Health researchers report.
Source: news-medical.net